biostudies-literatureMachado FJDMGovernment of NavarraInstituto de Salud Carlos IIIRICORS-ICTUSCIBERCV4379https://www.ebi.ac.uk/biostudies/studies/S-EPMC11050408biostudies-literatureUnknown25(8)Accurate etiologic diagnosis provides an appropriate secondary prevention and better prognosis in ischemic stroke (IS) patients; still, 45% of IS are cryptogenic, urging us to enhance diagnostic precision. We have studied the transcriptomic content of plasma extracellular vesicles (EVs) (<i>n</i> = 21) to identify potential biomarkers of IS etiologies. The proteins encoded by the selected genes were measured in the sera of IS patients (<i>n</i> = 114) and in hypertensive patients with (<i>n</i> = 78) and without atrial fibrillation (AF) (<i>n</i> = 20). IGFBP-2, the most promising candidate, was studied using immunohistochemistry in the IS thrombi (<i>n</i> = 23) and atrium of AF patients (<i>n</i> = 13). In vitro, the IGFBP-2 blockade was analyzed using thromboelastometry and endothelial International journal of molecular sciencesTranscriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies.PMC11050408RD21/0006/0008PI21/00946PI22/00436MINERVA IIPI20/01319CB16/11/00483Machado FJDMGomez SUZandio BAymerich NRoncal CMunoz RMarta-Enguita JHerrera MMarta-Moreno JParamo-Fernandez JARodriguez JAOrbe JLopez BBermejo RGonzalez AfalseTranscriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies.Accurate etiologic diagnosis provides an appropriate secondary prevention and better prognosis in ischemic stroke (IS) patients; still, 45% of IS are cryptogenic, urging us to enhance diagnostic precision. We have studied the transcriptomic content of plasma extracellular vesicles (EVs) (<i>n</i> = 21) to identify potential biomarkers of IS etiologies. The proteins encoded by the selected genes were measured in the sera of IS patients (<i>n</i> = 114) and in hypertensive patients with (<i>n</i> = 78) and without atrial fibrillation (AF) (<i>n</i> = 20). IGFBP-2, the most promising candidate, was studied using immunohistochemistry in the IS thrombi (<i>n</i> = 23) and atrium of AF patients (<i>n</i> = 13). In vitro, the IGFBP-2 blockade was analyzed using thromboelastometry and endothelial 2024-01-01T00:00:00Z2024 Apr2026-05-20T03:16:02.544Z2026-05-20T03:07:44.472ZS-EPMC110504083867396310.3390/ijms25084379